eflornithine has been researched along with Prostatic Hyperplasia in 2 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harvengt, C | 1 |
| Dunzendorfer, U | 1 |
| Knöner, M | 1 |
2 other studies available for eflornithine and Prostatic Hyperplasia
| Article | Year |
|---|---|
Drugs recently released in Belgium. Eflornithine--finasteride.
Topics: Eflornithine; Finasteride; Humans; Male; Prostatic Hyperplasia | 1994 |
[Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma. An experimental and clinical study].
Topics: Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Antineoplastic Agents; Carboxy-Lyases; Ca | 1985 |